April 2 Product: Vanda Pharmaceuticals Fanapt Indication: Bipolar I disorder Vanda Pharmaceuticals Fanapt, originally approved in 2009 for schizophrenia, is now authorized to treat manic or mixed episodes in adults with bipolar I disorder
However, the largest Phase IIb trial involving 536 participants failed to demonstrate statistically significant weight loss compared to placebo at the primary 12-week endpoint, leading to development termination in 2007
Regular B12 injections may promote hair growth, prevent thinning, and help maintain healthy, strong hair
Outcome measures include neurological severity scoring, rotarod and beam walk performance, histological assessment of lesion volume, and immunohistochemistry for axonal markers and myelin basic protein
Ive noticed real benefits from the IV vitamin drips and Red light therapy
Major injuries and trauma